Abstract
The use of incretin-based therapies, such as DPP-4 inhibitors and GLP-1 receptor agonists, has increased dramatically due to their efficacy, low risk of hypoglycemia, and potential for preserving beta-cell function. Based on their effects on glycemic control and the likelihood of aiding in weight loss, GLP-1 receptor agonists provide a unique treatment option for people with type 2 diabetes. The potential benefit of incretin-based therapies in the treatment of type 2 diabetes patients and cardiovascular disease is currently an active area of research. While the potential benefits of incretin-based therapies in cardiovascular risk reduction are promising, results from ongoing outcomes-based studies will help determine the role of these agents in diabetes management.
